Publications by authors named "Mitchell Revill"

Claim this Profile
F
Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer.
Alessia Catozzi, Maria Peiris Pagès, Sam Humphrey, Mitchell Revill, Derrick Morgan

Cell Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer.
Alessia Catozzi, Maria Peiris-Pagès, Sam Humphrey, Mitchell Revill, Derrick Morgan

bioRxiv· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.
Maximilian W Schenk, Sam Humphrey, A S Md Mukarram Hossain, Mitchell Revill, Sarah Pearsall

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.
Sarah M Pearsall, Sam Humphrey, Mitchell Revill, Derrick Morgan, Kristopher K Frese

J Thorac Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.
Kathryn L Simpson, Ruth Stoney, Kristopher K Frese, Nicole Simms, William Rowe, Mitchell Revill

Nat Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Nicola J Curtis, Lorraine Mooney, Lorna Hopcroft, Filippos Michopoulos, Nichola Whalley, Mitchell Revill

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sarah J Ross, Alexey S Revenko, Lyndsey L Hanson, Rebecca Ellston, Anna Staniszewska, Mitchell Revill

Sci Transl Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis